FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004402857> ?p ?o ?g. }

• W2004402857 endingPage "325" @default.
• W2004402857 startingPage "315" @default.
• W2004402857 abstract "The 26S proteasome is a proteolytic enzyme found in both cytoplasm and nucleus. In this study, we examined the differential expression of proteasome inhibitor bortezomib-induced proteins in p53-deficient 4T1 cells. It was found that GRP78 and TCEB2 were over-expressed in response to treatment with bortezomib for 24 h. Next, we analyzed the expression of intracellular proteins in response to treatment with 100 nM bortezomib for 24 h by label-free LC-MS/MS. These analyses showed that Hsp70, the 26S proteasome non-ATPase regulatory subunit 14 and sequestosome 1 were increased at least 2 fold in p53-deficient 4T1 cells. The proteins identified by label-free LC-MS/MS were then analyzed by Ingenuity Pathway Analysis (IPA) Tool to determine biological networks affected by inhibition of the 26S proteasome. The analysis results showed that post-translational modifications, protein folding, DNA replication, energy production and nucleic acid metabolism were found to be among the top functions affected by the 26S proteasome inhibition. The biological network analysis indicated that ubiquitin may be the central regulator of the pathways modulated after bortezomib-treatment. Further investigation of the mechanism of the proteins modulated in response to the proteasomal inhibition may lead to the design of more effective and novel therapeutic strategies for cancer. Although the proteasome inhibitor bortezomib is approved and used for the treatment of human cancer (multiple myeloma), the mechanism of action is not entirely understood. A number of studies showed that proteasome inhibitors induced apoptosis through upregulation of tumor suppressor protein p53. However, the role of tumor suppressor protein p53 in bortezomib-induced apoptosis is controversial and not well-understood. The tumor suppressor p53 is mutated in at least 50% of human cancers and is strongly induced by proteasomal inhibition. Some also reported that the proteasome inhibitor can induce apoptosis in a p53-independent manner. Also, it is reported that Noxa, a target of p53, is induced in response to proteasomal inhibition in a p53-independent manner. However, we have also previously reported that neither Puma nor Noxa are induced by proteasomal inhibition in p53-null 4T1 breast cancer cells, which is commonly used for in vivo breast cancer tumor models. The current results provided additional targets of proteasome inhibitor bortezomib and may therefore help in understanding the p53-independent mechanism of apoptosis induction by proteasome inhibitors. In addition, the results presented in this current study report for the first time that proteasomal subunit Psmd14, anti-apoptotic GRP78, anti apoptotic protein Card10, Dffb, Traf3 and Trp53bp2 are regulated and overexpressed in response to proteasome inhibitor bortezomib in p53-deficient 4T1 cells. Therefore, novel therapeutic strategies targeting these anti-apoptotic or pro-apoptotic proteins as well as inhibiting the proteasome simultaneously may be more effective against cancer cells. The proteins identified here present new avenues for the development of anti-cancer drugs." @default.
• W2004402857 created "2016-06-24" @default.
• W2004402857 creator A5001871651 @default.
• W2004402857 creator A5020479633 @default.
• W2004402857 creator A5047890987 @default.
• W2004402857 creator A5060565512 @default.
• W2004402857 creator A5067279763 @default.
• W2004402857 creator A5087482377 @default.
• W2004402857 date "2015-01-01" @default.
• W2004402857 modified "2023-10-01" @default.
• W2004402857 title "A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line" @default.
• W2004402857 cites W1503285048 @default.
• W2004402857 cites W1518640128 @default.
• W2004402857 cites W1654790906 @default.
• W2004402857 cites W1964819733 @default.
• W2004402857 cites W1965253007 @default.
• W2004402857 cites W1972076184 @default.
• W2004402857 cites W1995997074 @default.
• W2004402857 cites W1998513492 @default.
• W2004402857 cites W2002914635 @default.
• W2004402857 cites W2005848420 @default.
• W2004402857 cites W2010163650 @default.
• W2004402857 cites W2010301504 @default.
• W2004402857 cites W2015883486 @default.
• W2004402857 cites W2018082393 @default.
• W2004402857 cites W2037199116 @default.
• W2004402857 cites W2038139095 @default.
• W2004402857 cites W2048043603 @default.
• W2004402857 cites W2056769035 @default.
• W2004402857 cites W2056804360 @default.
• W2004402857 cites W2067653691 @default.
• W2004402857 cites W2068273299 @default.
• W2004402857 cites W2068464911 @default.
• W2004402857 cites W2068994409 @default.
• W2004402857 cites W2071358321 @default.
• W2004402857 cites W2078484286 @default.
• W2004402857 cites W2085349933 @default.
• W2004402857 cites W2097164847 @default.
• W2004402857 cites W2101605262 @default.
• W2004402857 cites W2105821343 @default.
• W2004402857 cites W2108235071 @default.
• W2004402857 cites W2110436086 @default.
• W2004402857 cites W2118937204 @default.
• W2004402857 cites W2125503650 @default.
• W2004402857 cites W2132590594 @default.
• W2004402857 cites W2134212242 @default.
• W2004402857 cites W2140687548 @default.
• W2004402857 cites W2147368157 @default.
• W2004402857 cites W2163498786 @default.
• W2004402857 cites W2166761147 @default.
• W2004402857 cites W2171071516 @default.
• W2004402857 cites W2320360082 @default.
• W2004402857 doi "https://doi.org/10.1016/j.jprot.2014.09.010" @default.
• W2004402857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25305590" @default.
• W2004402857 hasPublicationYear "2015" @default.
• W2004402857 type Work @default.
• W2004402857 sameAs 2004402857 @default.
• W2004402857 citedByCount "22" @default.
• W2004402857 countsByYear W20044028572014 @default.
• W2004402857 countsByYear W20044028572015 @default.
• W2004402857 countsByYear W20044028572016 @default.
• W2004402857 countsByYear W20044028572017 @default.
• W2004402857 countsByYear W20044028572018 @default.
• W2004402857 countsByYear W20044028572019 @default.
• W2004402857 countsByYear W20044028572020 @default.
• W2004402857 countsByYear W20044028572021 @default.
• W2004402857 countsByYear W20044028572022 @default.
• W2004402857 countsByYear W20044028572023 @default.
• W2004402857 crossrefType "journal-article" @default.
• W2004402857 hasAuthorship W2004402857A5001871651 @default.
• W2004402857 hasAuthorship W2004402857A5020479633 @default.
• W2004402857 hasAuthorship W2004402857A5047890987 @default.
• W2004402857 hasAuthorship W2004402857A5060565512 @default.
• W2004402857 hasAuthorship W2004402857A5067279763 @default.
• W2004402857 hasAuthorship W2004402857A5087482377 @default.
• W2004402857 hasConcept C104317684 @default.
• W2004402857 hasConcept C121608353 @default.
• W2004402857 hasConcept C127561419 @default.
• W2004402857 hasConcept C185592680 @default.
• W2004402857 hasConcept C190283241 @default.
• W2004402857 hasConcept C203014093 @default.
• W2004402857 hasConcept C25602115 @default.
• W2004402857 hasConcept C27740335 @default.
• W2004402857 hasConcept C2776364478 @default.
• W2004402857 hasConcept C2777478702 @default.
• W2004402857 hasConcept C2778367456 @default.
• W2004402857 hasConcept C2992195973 @default.
• W2004402857 hasConcept C502942594 @default.
• W2004402857 hasConcept C54355233 @default.
• W2004402857 hasConcept C55493867 @default.
• W2004402857 hasConcept C86803240 @default.
• W2004402857 hasConcept C95444343 @default.
• W2004402857 hasConcept C96232424 @default.
• W2004402857 hasConceptScore W2004402857C104317684 @default.
• W2004402857 hasConceptScore W2004402857C121608353 @default.
• W2004402857 hasConceptScore W2004402857C127561419 @default.
• W2004402857 hasConceptScore W2004402857C185592680 @default.
• W2004402857 hasConceptScore W2004402857C190283241 @default.

• next